38results about How to "Lessen lung damage" patented technology

Methods of treating conditions associated with lipid oxidation or microbial proliferation include the step of administering a composition comprising a pharmacologically effective amount of an antioxidant or antimicrobial lung surfactant protein compound. Peptides derived from lung surfactant protein compounds possess lipid oxidation inhibiting and / or antimicrobial properties.

Provided is a novel vaccine for preventing COVID-19, the nucleotide sequence of an antigen of the novel vaccine is SEQ NO: 1, the amino acid sequence of the antigen of the novel vaccine is SEQ NO: 2,and the antigen of the vaccine comprises two functional parts: an S protein receptor binding structural domain capable of inducing a specific neutralizing antibody and a T cell related N protein truncated peptide fragment capable of inducing and activating effector T cells; The vaccine disclosed by the invention has the characteristics that the T cell related N protein truncated peptide fragment has weak capability of inducing the generation of the N protein antibody, so that a vaccine inoculator and a COVID-19 infected patient can be identified by using the N protein antibody, and the vaccineantigen does not induce the generation of the N protein antibody, so that lung injuries can be reduced, and the vaccine is safer. The cell vaccine disclosed by the invention is low in manufacturing cost, and can induce generation of virus-specific neutralizing antibodies and T cell immune response.

Compounds that inhibit p38α MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.

The invention discloses a Changshanhuyou tangelo and Quzhouhertao peach compound juice drink, and belongs to the technical field of drinks and preparations of the drinks. The drink is prepared by components in parts by weight as follows: 10-12 parts of Changshanhuyou tangelo juice, 20-24 parts of Quzhouhertao peach juice, 5-7 parts of liquorice extracting solutions, 5-7 parts of red autumn sunflower extracting solutions and the balance of water, wherein the total number of parts of the total volume of the drink is 100. The provided compound juice drink has tempting color and sour, sweet and mouthwatering taste, no edible essence and pigment are added, and the original characteristics of raw materials are kept to the greatest extent; and the compound juice drink has the efficacy of decreasing internal heat, replenishing strength and keeping health and is suitable for people of all ages and both sexes.

Compounds that inhibit p38α MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.

The present invention relates to inhibitors of C5a for use in the treatment of pneumonia, especially viral pneumonia. The invention also relates to the use of inhibitors of C5a in the preparation of a pharmaceutical composition for the treatment of pneumonia, especially viral pneumonia. The inventors further relates to methods for the treatment of pneumonia, especially viral pneumonia, comprising the step of administering a therapeutic amount of an inhibitor of C5a to a subject in need thereof.

The invention provides a pharmaceutical composition for treating viral infection of respiratory system. The pharmaceutical composition contains chloroquine and a sputum-removing drug. The sputum-removing drug is selected from at least one of acetylcysteine, ambroxol or ammonium chloride. The invention provides a preparation method of the pharmaceutical composition for preventing and treating diseases caused by virus infection of a human respiratory system. The medicine composition of the chloroquine and sputum-removing drug is prepared into a spray, an aerosol or an inhalation preparation forpreventing and treating the diseases caused by the virus infection of the human respiratory system.

The invention relates to a special endotracheal tube for lung transplantation, which is particularly used for supplying air for lungs of a patient during lung transplantation or pulmonary resection and belongs to the technical field of medical instruments. The special endotracheal tube mainly comprises an outer cannula and an inner cannula, and the inner cannula is fixed in the outer cannula. An outer cannula air sac is arranged on the outer surface of the middle of the outer cannula. A first inner cannula air sac and a second inner cannula air sac are successively arranged on the outer surface of the lower portion of the inner cannula. The special endotracheal tube is simple, compact and reasonable in structure and simple and convenient in operation, the single inner cannula is used for carrying out breathing support for the lung of the patient, the pressure of the trachea is low, and the possibility of injury of the lung on a non-surgical side due to mechanical breathing is reduced; the bronchia on a surgical side is closed by the air sacs, so that liquid of the lung on the surgical side cannot enter the non-surgical side and the trachea, and breathing support leakage can be avoided while the bronchia is sutured; and the inner cannula is taken out after surgery is finished, the outer cannula is remained to carry out breathing support, and sufferings caused by replacement of a catheter and risks of injury of the trachea are avoided.

The invention discloses an application of a black barley leaven in relieving lung injury and intestinal flora disorder and relates to the technical field of medicines and healthcare products. Lactobacillus plantarum is a fermenting strain used by the leaven. The application of the black barley leaven in relieving lung injury and intestinal flora disorder caused by cooking lampblack has the technical effects of obviously relieving pneumonemia and improving intestinal flora disorder.

The invention concerns the use of a bombesin / gastrin releasing peptide antagonist in the treatment of inflammatory and immune-mediated inflammatory conditions, in particular sepsis, acute lung injury and rheumatoid arthritis as well as for the treatment or prophylaxis of brain disorders, preferably bipolar disorder, and in particular the different forms and / or subforms of bipolar disorder, such as mania, acute mania, severe mania, hypomania, depression, moderate depression, dysthymia, severe depression, episodes of mania and / or depression, psychosis / psychotic symptoms (e.g. hallucinations, delusions), mixed bipolar state, bipolar I disorder, bipolar II disorder and / or rapid-cycling bipolar disorder. In particular, specific nonapeptides with antagonist properties against bombesin or bombesin-like peptides, such as the gastrin releasing peptide, may be used in the treatment of inflammatory and immune-mediated inflammatory conditions as well as brain disorders.

Methods for the reversal of hemorrhagic shock or hemorrhagic trauma.

The invention discloses a preparation method of a polyphyllin nano-liposome dry powder inhalation, which comprises the following steps: preparing liposome by adopting a film dispersion method, a reversed-phase evaporation method or a solvent injection method, and then drying by adopting a spray drying method or a freeze drying method to obtain the polyphyllin nano-liposome dry powder inhalation. The polyphyllin nano-liposome dry powder inhalation prepared by the invention has the advantages that the production conditions are easy to control, the particle size distribution of prepared particles is relatively concentrated, the stability, the flowability and the dispersity are good, the potential is 25-32mV, and the medicine can be slowly released within 16-24h. The polyphyllin nano-liposome dry powder inhalation can be used for preparing a medicine for preventing or treating 2019-nCoV(nCoV).

The present disclosure provides the use of mesenchymal stem cells (MSC) in the treatment of viral infection and / or complications caused by the viral infection. MSC can highly express multiple antioxidative stress genes and secrete multiple antioxidative stress factors under the stimulation of oxidative stress, inhibit inflammatory reaction and excessive activation of immune cells, thus improving inflammatory indexes and myocardial injury indexes of human bodies. MSC can regulate the expression profile of monocyte genes and monocyte toxicity genes in patients with viral infection, inhibit the excessive immune response, protect alveolar function, and reduce the damage of lung and whole body organs in patients with viral infection. MSC can regulate the expression of antivirus-related genes and coagulation-related genes of terminally differentiated cell subsets in patients with viral infection, inhibit the excessive activation of monocytes in patients with viral infection, and effectively treat the complications of patients with viral infection.

A system and method for measuring alveolar performance during ventilation using a microphone positioned adjacent to the distal end of a ventilation tube. The microphone is connected to a monitor that filters the signals received from the microphone to eliminate unwanted noise, such as that caused by the heart and turbulent airflow through the large airways of the lungs. The desired signals are then amplified and displayed on a graph as a function of lung volume during inflation. A clinician may take appropriate ventilation strategies based on the results displayed by the system to avoid ventilator induced lung injuries and decrease the mortality rates of patients having acute respiratory distress syndrome.

Systems and methods for gas exchange in a patient are provided that use an external circuit to cause oxygenation perfusion in a patient's body cavity (such as the abdomen) using an inert chemical (e.g., perfluorocarbon), independent of the lungs. The external circuit includes components configured to control properties of the chemical, including temperature, flow rate, pressure, oxygenation percentage, carbon dioxide percentage. The system also includes safety features to reduce the likelihood of injury to the patient. Each of the safety features and chemical properties can be controlled by a healthcare worker, such as a physician, nurse, or emergency operator, for a particular patient.

The invention discloses a cochliobolus quinone B derivative, a production strain and applications. The structural formula of the derivative is shown as the description. The derivative is produced by aBipolaris sorokiniana KLBMPSM007 obtained through separating and screening; and the Bipolaris sorokiniana KLBMPSM007 has been deposited in a common microorganism center of the China committee for culture collection of microorganisms, the deposited time is on 5th June, 2017, and the deposited number is CGMCC NO. 13900. The compound can significantly increase the survival rates of mice infected bypseudomonas aeruginosa, reduce lung injury and bacterial diffusion, and show good biological effects of against pseudomonas aeruginosa infection; and the occurrence of autophagy of alveolar macrophagecan be directly induced through compound processing, so that the macrophage can be promoted to perform identification, phagocytosis and degradation on the pseudomonas aeruginosa, and the invading ofthe pseudomonas aeruginosa can be resisted.

The invention relates to a traditional Chinese medicine composition for preventing and treating lung injury due to radioactive radon and daughters thereof, that is a radon lung injury protective agent, and particularly is to develop a radon lung injury protective agent which can prevent and treat pneumonia, pulmonary fibrosis, and lung cancer caused by high radon exposure. The invention comprises traditional Chinese medicines which can tonify qi and nourish yin, clear heat and invigorate blood, strengthen body resistance and remove toxin, can reduce lung injury caused by high radon exposure, can be used for the prevention and treatment of pneumonia, pulmonary fibrosis, and lung cancer caused by radioactive radon and daughters thereof.

The invention discloses an application of FUNDC1 in treating acute respiratory distress syndrome and belongs to the technical field of biology. The present invention provides the application of the FUNDC1 in preparing products for preventing and / or treating inflammatory diseases. The mechanism of the FUNDC1 in preventing and / or treating inflammatory diseases is mainly to reduce lung injury by mediating mitochondrial autophagy to inhibit activation and expansion of inflammatory reactions induced by an ROS-NLRP3 signaling pathway. The invention provides the application of the FUNDC1 in preparingproduct for preventing and / or treating acute respiratory distress syndrome. The product provided by the invention can reduce lung injury by inhibiting inflammatory reactions by promoting autophagy during ARDS period. The FUNDC1 is expected to become a new target for ARDS treatment and has a wide application prospect.

The invention belongs to the technical field of biological medicines, and discloses application of intervening BOK in preparation of a medicine for treating novel coronavirus pneumonia. In order to find a new immunotherapy scheme for comprehensive treatment of novel coronavirus pneumonia, the research on the lung tissue of novel coronavirus pneumonia patients finds that the expression quantity of BOK in the lung tissue cell of the novel coronavirus pneumonia patients is increased, BOK gene knockout can inhibit the apoptosis of human lung cells and vascular endothelial cells induced by a novel coronavirus membrane protein, and BOK knockdown by injecting lentivirus into the trachea of a mouse to express shRNA (short hairpin Ribonucleic Acid) aiming at BOK can inhibit the apoptosis of the lung tissue induced by the novel coronavirus membrane protein, which indicates that BOK is expected to be applied to the comprehensive treatment of the novel coronavirus pneumonia and is prepared into the form of a medicine for treating the novel coronavirus pneumonia, which can relieve lung injury and alveolar cavity fluid infiltration of the novel coronavirus pneumonia patients, and is suitable for protecting lung tissues and organs in the novel coronavirus pneumonia process.

The invention discloses an application of medical ozone in preparation of a medicine or preparation for inhibiting or treating sepsis complications caused by human infectious coronavirus, particularlynoval coronavirus 2019, and belongs to the field of biomedicines. According to the invention, medical ozone is used for actively inducing an endogenous anti-inflammatory mechanism to relieve sepsis lung injury, namely, ALI is treated without being limited by a certain single target point on a regulation and control membrane and a related single mechanism of the target, but the ALI is relieved from immunoregulation by actively inducing SOCS3 expression through AMPK to inhibit TLR4-p38-TF / MMP-9. The invention provides a brand-new thought and an excellent target for researching and developing anew anti-ALI drug.

The invention relates to the technical field of medical equipment, and discloses a respirator and a using method thereof. The respirator comprises an expiration flow sensor, an air supply flow sensorand a plurality of pressure sensors, a central processing unit, pressure adjusting equipment, an air supply gun and an exhalation valve, wherein the pressure sensors are used for measuring the air supply flow pressure and the expiration flow pressure and arranged on an air supply pipe and an expiration pipe; the central processing unit is used for receiving the data of the air supply flow sensor and the expiration flow sensor, comparing, integrating and calculating the data of the air supply flow and the expiration flow, and controlling the pressure adjusting equipment according to the integrated and calculated data and the data of the plurality of pressure sensors; the pressure adjusting equipment is used for adjusting the pressure of the air supply flow according to an instruction of thecentral processing unit and adjusting the pressure of the air supply flow; the air supply gun is used for conveying airflow with corresponding pressure according to data of the pressure adjusting equipment; and the exhalation valve is used for controlling and exhausting exhalation air flow. According to the respirator and the using method, the treatment success rate of the ARDS patient can be increased.

The invention discloses a traditional Chinese medicine composition for treating acute lung injury and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine compound preparations. The traditional Chinese medicine composition for treating acute lung injury is prepared from the following raw material medicines in parts by weight: 5-20 parts of raw ephedra, 5-20 parts of rhizoma cimicifugae, 5-30 parts of angelica sinensis, 5-30 parts of rhizoma anemarrhenae, 5-40 parts of radix polygonati officinalis, 5-30 parts of scutellaria baicalensis, 5-30 parts of radix paeoniae alba, 5-40 parts of asparagus fern, 5-40 parts of artemisia apiacea, 5-40 parts of turtle shell, 5-20 parts of amomum tsao-ko, 5-30 parts of mangnolia officinalis, 5-50 parts of gypsum, 5-40 parts of rhizoma atractylodis and 5-20 parts of liquorice. According to the invention, the colonization of pathogenic bacteria is prevented by regulating the structural distribution and composition of intestinal flora and up-regulating the immune response of a body. The feed additive can improve the imbalance of intestinal flora, increase beneficial flora capable of generating short-chain fatty acid, inhibit harmful flora and play a positive role in regulating flora. The traditional Chinese medicine composition has an obvious treatment effect on acute lung injury and has a good clinical application prospect.

Compounds that inhibit p38α MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.

The invention provides application of kaempferol 3-glucorhamnoside in preparation of a medicine for treating systemic severe sepsis, and belongs to the technical field of biological medicines. The inventor of the invention finds that the kaempferol 3-glucorhamnoside can improve and treat the severe sepsis by reducing TNF-alpha, IL-6 increase and IL-10 decrease caused by severe sepsis in serum, reducing TNF-alpha, IL-6 increase and IL-10 decrease caused by severe sepsis in the liver, reducing TNF-alpha, IL-6 increase and IL-10 decrease caused by severe sepsis in the lung, and reducing TNF-alpha, IL-6 increase and IL-10 decrease caused by severe sepsis in the spleen. Secondly, the kaempferol 3-glucorhamnoside can improve and treat the severe sepsis by reducing lung injury caused by the severe sepsis and inhibiting increase of phosphorylation degree of ERK1 / 2, JNK and p38 and increase of phosphorylation degree of I kappa B and NF-kappa B caused by severe sepsis. Therefore, the kaempferol3-glucorhamnoside can be used for preparing a potential medicine for treating diseases related to the systemic severe sepsis.